InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment

InMed Pharmaceuticals Inc. (NASDAQ: INM) has unveiled promising preclinical data for its drug candidate INM-901, demonstrating significant anti-inflammatory effects in models of neuroinflammation related to Alzheimer's disease. The compound achieved a dose-dependent reduction in key inflammatory markers, including cytokines IL-6, IL-1β, IL-2, KC/Gro, and the inflammasome marker NLRP3, which are implicated in the progression of Alzheimer's. Notably, INM-901's effects were observed independently of amyloid beta or tau pathology, suggesting a novel mechanism of action that could broaden its applicability in treating neurodegenerative diseases.

INM-901, an orally administered compound targeting CB1/CB2 receptors and PPARs, has also shown potential in improving cognition and behavior in long-term animal studies. These findings underscore the compound's therapeutic promise and support its advancement through further preclinical and IND-enabling studies, with Alzheimer's disease as the lead indication. For more details on the study, visit https://ibn.fm/HBoFJ.